Metformin safety posttransplantation-trials and tribulations

American Journal of Transplantation

Volumn 12, Issue 3, 2012, Pages 796-

  Sharif, A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN; LACTIC ACID; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LETTER; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RISK; RISK BENEFIT ANALYSIS;

EID: 84857653753     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03920.x     Document Type: Letter

References (5)

1. Larsen J,. Potential risks of Metformin in transplant patients. Am J Transplant 2012; doi
2. Sharif A,. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant 2011; 11: 1376-1381.
3. Chang CT, Chen YC, Fang JT, Huang CC,. Metformin-associated lactic acidosis: Case reports and literature review. J Nephrol 2002; 15: 398-402.
4. Lalau JD, Race JM,. Lactic acidosis in metformin-treated patients: Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377-384.
5. Morales AI, Detaille D, Prieto M, et al,. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondrial-dependent pathway. Kidney Int 2010; 77: 861-869.